Lantern Pharma
LTRN
25 hedge funds and large institutions have $15.7M invested in Lantern Pharma in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
14% more funds holding
Funds holding: 22 → 25 (+3)
0.48% more ownership
Funds ownership: 12.05% → 12.53% (+0.48%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less capital invested
Capital invested by funds: $19.7M → $15.7M (-$4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$335K |
| 2 |
State Street
Boston,
Massachusetts
|
+$331K |
| 3 |
Millennium Management
New York
|
+$164K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$141K |
| 5 |
WWM
Wolff Wiese Magana
Carslbad,
California
|
+$90.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$395K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$83.7K |
| 3 |
Morgan Stanley
New York
|
-$56.6K |
| 4 |
BlackRock
New York
|
-$26.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$7.34K |
LTRN Hedge Fund Activity: Q3 2021 in Review
25 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q3 2021, worth a combined $15.7M — down 20% from $19.7M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new LTRN positions and 2 closed out — a net gain of 3 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was Raymond James & Associates, opening a new position worth an estimated $335K. The largest seller was Corriente Advisors, cutting an estimated $395K.
- 25 institutional investors held Lantern Pharma (LTRN) as of Q3 2021, up from 22 in Q2 2021.
- Funds reported $15.7M of Lantern Pharma stock for Q3 2021, down 20% quarter-over-quarter.
- 5 funds opened new Lantern Pharma positions in Q3 2021 and 2 closed out, a net change of +3 holders.
- The largest Lantern Pharma buyer in Q3 2021 was Raymond James & Associates, an estimated $335K added.
- The largest Lantern Pharma seller in Q3 2021 was Corriente Advisors, an estimated $395K sold.
Based on aggregated 13F filings for Q3 2021.